Edward M. Rudnic, PhD, is a pharmaceutical executive and entrepreneur with an extensive background in the biopharmaceutical industry. He has served in leading capacities as the head of several start-ups, public companies, and venture-related funds/companies and is currently the Chief Executive Officer of DisperSol Technologies, a platform technology company with late-stage clinical programs. Dr. Rudnic was founder, chairman and CEO of MiddleBrook Pharmaceuticals (Nasdaq: MBRK, previously Advancis; Nasdaq: AVNC), where he founded the company, took it public on the NASDAQ, and lead the development of FDA approved anti-infective products.

Prior to founding MiddleBrook, he was Senior Vice President, Development and Technical Operations for Shire Laboratories, where he was the lead inventor of Carbatrol/Equetro with cumulative sales of over $2 billion to date, and co-inventor of Adderall XR with cumulative sales of over $20 billion to date. Dr. Rudnic serves as an adjunct associate professor for the University of Maryland Pharmaceutical Sciences Center, and an adjunct professor at the University of Rhode Island Department of Pharmaceutical Sciences. Dr. Rudnic holds a B.S. in Pharmacy, a M.S. in Pharmaceutics, and a PhD in Pharmaceutical Sciences from the University of Rhode Island and serves on advisory boards at URI.